dc.contributor.author | Díez, José María | |
dc.contributor.author | Romero, Carolina | |
dc.contributor.author | Vergara-Alert, Júlia | |
dc.contributor.author | Belló-Perez, Melissa | |
dc.contributor.author | Rodon, Jordi | |
dc.contributor.author | Honrubia, José Manuel | |
dc.contributor.author | Segalés, Joaquim | |
dc.contributor.author | Sola, Isabel | |
dc.contributor.author | Enjuanes, Luis | |
dc.contributor.author | Gajardo, Rodrigo | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2021-02-17T08:05:33Z | |
dc.date.available | 2021-02-17T08:05:33Z | |
dc.date.issued | 2020-09-09 | |
dc.identifier.citation | Díez, José María, Carolina Romero, Júlia Vergara-Alert, Melissa Belló-Perez, Jordi Rodon, José Manuel Honrubia, Joaquim Segalés, Isabel Sola, Luis Enjuanes, and Rodrigo Gajardo. 2020. "Cross-Neutralization Activity Against SARS-Cov-2 Is Present In Currently Available Intravenous Immunoglobulins". Immunotherapy 12 (17): 1247-1255. doi:10.2217/imt-2020-0220. | ca |
dc.identifier.issn | 1750-743X | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/1093 | |
dc.description.abstract | Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19. | ca |
dc.format.extent | 9 | ca |
dc.language.iso | eng | ca |
dc.publisher | Future Medicine | ca |
dc.relation.ispartof | Immunotherapy | ca |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | https://doi.org/10.2217/imt-2020-0220 | ca |
dc.contributor.group | Sanitat Animal | ca |